FDA approves Brekiya®, a dihydroergotamine mesylate autoinjector for the acute treatment of migraine with or without aura and cluster headaches in adults.
New research reveals healthier diets delay menarche while inflammatory diets accelerate it, potentially impacting long-term health outcomes in women regardless of BMI.
A new study found that 1 in 3 rheumatoid arthritis patients with normal heart function on standard tests had hidden heart strain detectable only through advanced imaging, with anemia emerging as the strongest predictor.
April’s FDA approvals feature first-in-class therapies, targeted biologics, expanded indications, and innovative delivery systems across allergy, endocrinology, rheumatology, oncology, infectious diseases, and more.